Ren PW, et al. – The physicians performed this systematic review to critically evaluate the efficacy and safety of Kangfuxinye enema combined with mesalamine for the ulcerative colitis (UC) patients and in addition to grade the quality of evidence by using the GRADE (grading of recommendations, assessment, development, and evaluation) approach. Kangfuxinye enema combined with mesalamine was weakly recommended due to very low to moderate quality of available evidence by the GRADE approach although Kangfuxinye enema appeared effective and safe for treating UC patients in this systematic review.

• The physicians performed a literature search in the Cochrane Library, MEDLINE, EMBASE, CBM, CNKI, VIP, and WanFang Databases.
• The search restrictions were patients with UC and RCTs.
• Except for Kangfuxinye with mesalamine, studies including other treatments were excluded.

• The inclusion criteria was met by 19 studies.
• The physicians found significant benefits of Kangfuxinye combined with mesalamine compared to mesalamine alone in improving response rate as well as reducing the recurrence rate and inflammation rate.
• Meanwhile, the increase of the adverse events rate was not observed.
• Moreover, the symptoms remission rate and the cure time were insignificant statistically.
• Also, GRADE results demonstrated that the quality of evidence about the above 6 outcomes was rated from very low to moderate quality.